We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 19, 2020

Umbralisib in Patients With CLL Intolerant to BTK or PI3Kδ Inhibitor Therapy

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients With CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
Blood 2020 Dec 01;[EPub Ahead of Print], AR Mato, N Ghosh, SJ Schuster, N Lamanna, JM Pagel, IW Flinn, J Barrientos, KR Rai, JA Reeves, BD Cheson, PM Barr, S Kambhampati, F Lansigan, JJ Pu, AP Skarbnik, LE Roeker, G Fonseca, A Sitlinger, IS Hamadeh, C Dorsey, N LaRatta, H Weissbrot, ET Luning Prak, PY Tsao, D Paskalis, P Sportelli, HP Miskin, MS Weiss, J Svoboda, DM Brander

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading